Project 172053

Polymeric membrane lactobacillus formulation for use in type II diabetes.

172053

Polymeric membrane lactobacillus formulation for use in type II diabetes.

$386,196
Project Information
Study Type: Unclear
Research Theme: Biomedical
Institution & Funding
Principal Investigator(s): Prakash, Satya
Institution: McGill University
CIHR Institute: Nutrition, Metabolism and Diabetes
Program: Operating Grant
Peer Review Committee: Pharmaceutical Sciences
Competition Year: 2008
Term: 3 yrs 0 mth
Abstract Summary

Recent changes in human diet and lifestyle have resulted in a dramatic increase in number of diabetics worldwide. The continuous use of currently available synthetic drugs has associated limitations. This proposal is an attempt to address the urgent need to develop a safe, natural and economical strategy to treat or prevent the emerging global epidemic of type 2 diabetes. A novel oral artificial cell microcapsule formulation incorporating live feruloyl esterase active probiotic bacterial cells has been developed. We have obtained very encouraging preliminary results indicating the potential of this formulation in type 2 diabetes. Here, we propose to investigate the feasibility, suitability, mode of action and pre-clinical efficacy of this formulation in an experimental animal model. If successful, this formulation will be used to treat and/or prevent type 2 diabetes. In addition, this study will be a step towards exploiting the important potential of non-pathogenic FAE active bacterial cells for future clinical applications.

No special research characteristics identified

This project does not include any of the advanced research characteristics tracked in our database.

Keywords
Diabetes Mellitus Feruloyl Esterase Microcpsule Polymeric Membrane